ClinicalTrials.gg
CompletedNCT04679896PARTNERUpdated Feb 13, 2024

Post Marketing Study of MagnetOs Putty Compared to Local Autograft in Patients Undergoing Posterolateral Lumbar Fusion

An interventional study of MagnetOs Putty in Degenerative Disc Disease and Spine Fusion, sponsored by Kuros Biosurgery AG. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Kuros Biosurgery AG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
85th of 141
30 · median 57
Started
2021
with 13 others
No phase
90 of 232
15 open now
Registered
171st of 232
by date

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 85th largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2021, is one of 90 with no phase, and was the 171st registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is a phase IV post-marketing study for MagnetOs Putty. MagnetOs Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with leg pain and/or back pain and undergoing spinal fusion surgery.

In this study, MagnetOs Putty will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine.

Read the detailed description

In this study, following a screening period of a maximum of 30 days, 30 patients will undergo up to a three-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Putty on the assigned side of the spine and local autograft bone on the other at the diseased levels. They will be followed up at discharge, Week 2, Week 6, Month 3, Month 6, and Month 12. An interim analysis will be performed once 15 patients have completed their Month 6 visit and have measurements for the endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month 12.

In this study, MagnetOs Putty will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Putty will be used as a bone graft extender mixed with autograft in a 1:1 vol.% in patients with with leg pain and/or back pain requiring up to three-level instrumented posterolateral lumbar fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.

Radiographs will be obtained at Screening, Day 0, Week 6, Month 3. CT scans will only be obtained at Month 6 and Month 12.

03

Conditions studied

  • Degenerative Disc Disease
  • Spine Fusion

Keywords

  • Degenerative Disc Disease
  • Spine Fusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to read/be read, understand, and provide written and has signed the Review Board (IRB) approved informed consent.
  2. Male or female patient ≥ 18 years old.
  3. Patients with leg pain and/or back pain requiring up to three-level instrumented posterolateral lumbar fusion (L2 - S1).
  4. Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Requires > three-level fusion or expected to need secondary intervention within one year following surgery.
  2. To treat conditions in which general bone grafting is not advisable.
  3. In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
  4. In case of significant vascular impairment proximal to the graft site.
  5. In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta or Paget's Disease) that affect bone or wound healing.
  6. In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
  7. When intraoperative soft tissue coverage is not planned or possible.
  8. Undergoing any procedure that allows MagnetOs to come in direct contact with the articular space.
  9. Receiving treatment with medication interfering with calcium metabolism.
  10. Women who are or intend to become pregnant within the next 12 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    MagnetOs Putty

    MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.

    Device: MagnetOs Putty

  • Other
    Local autograft

    Device: MagnetOs Putty

Interventions

  • DeviceMagnetOs Putty

    Procedure: Instrumented posterolateral spine fusion

06

What researchers measure

Primary outcomes

  1. Radiographic Fusion by CT Scan

    The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

    Time frame: Month 12

Secondary outcomes

  1. Radiographic Fusion by Plain Radiographs

    The rate of posterolateral lumbar fusion assessed by plain radiographs

    Time frame: Week 2, Week 6, Month 3

  2. Posterolateral lumbar fusion assessed by CT-scan

    The rate of posterolateral lumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes

    Time frame: Month 6

  3. Interbody lumbar fusion assessed by plain radiographs

    The rate of interbody lumbar fusion assessed by plain radiographs at Week 2, Week 6, Month 3, Month 6, and Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior vertebral bodies

    Time frame: Week 2, Week 6, Month 3, Month 6, Month 12

  4. Functional Outcome by Oswestry Disability Index

    Change in functional score using Oswestry Disability Index questionnaire. Patient-completed survey provides subjective percentage score for level of function (disability) in activities of daily living. Score rage 0-100 percent. The lower the percentages indicate higher functionality; 0-20% minimal disability, 80-100% significant disability.

    Time frame: Week 2, Week 6, Month 3, 6, and 12

  5. General, back and Leg Pain by Visual Analog Pain Scale

    Change in general, back and leg pain using Visual Analog Pain Scale score. The patient completed questionnaire is a unidimensional measure of pain intensity using a continuous scale comprised of a horizontal line 10 centimeters (100 mm) in length. The line is anchored by "no pain" (score of 0) and "worst imaginable pain". A higher score indicates greater pain intensity.

    Time frame: Week 2, Week 6, Month 3, 6, and 12

  6. Neurologic Status by Physical Exam

    Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for the lower extremities, specifically in reflexes, muscle strength, sensory, and straight leg raise.

    Time frame: Week 2, Week 6, Month 3, 6, and 12

  7. Success Rate

    Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery

    Time frame: Week 2, Week 6, Month 3, 6, and 12

Other outcomes

  1. Safety Endpoint - number of patients with Adverse Events

    The number of patients with Adverse Events from Screening up to Month 12 after surgery

    Time frame: 12 Months

  2. Safety Endpoint - number of patients with Serious Adverse Events

    The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery

    Time frame: 12 Months

  3. Safety Endpoint - number of patients with Adverse Device Effects

    The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery

    Time frame: 12 Months

  4. Safety Endpoint - number of patients with Device Related Complications

    The number of patients with any complications considered to device related with 12 months after surgery

    Time frame: 12 Months

  5. Health Economic - Duration of Surgery

    Duration of surgery in minutes

    Time frame: 12 Months

  6. Health Economic - Duration of Hospitalization

    Duration of hospital stay in days

    Time frame: 12 Months

  7. Health Economic - Return to Work

    Time to return to work in days

    Time frame: 12 Months

  8. Health Economic - Quality of Life

    Change in Quality of Life measurement using EuroQol 5D/5L scoring

    Time frame: Week 6, Month 3, 6, and 12

07

Study locations

1 site
  • Orthopaedic Institute of Western Kentucky
    Paducah, Kentucky 42001, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Aug 2023, 23 months.

Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's 23 months is below that.

Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2020
First posted
Dec 22, 2020
StartActual
Aug 13, 2021
Primary completionActual
Aug 2, 2023
CompletionActual
Dec 2, 2023
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04679896
Lead sponsor
Kuros Biosurgery AG
Collaborators
Orthopaedic Institute of Western Kentucky, Simplified Clinical Data Systems, LLC
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Aug 13, 2021
Primary completion
Aug 2, 2023
Completion
Dec 2, 2023
Last update
Feb 13, 2024

Study contacts

Pascal Longlade, MD
study director · Kuros BioSciences B.V.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion